Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...
The Faculty of Medicine at Imperial is a world-class teaching, learning and research environment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback